Skip to main content
. 2015 Mar 16;3(3):210–220. doi: 10.12998/wjcc.v3.i3.210

Figure 2.

Figure 2

Studies comparing outcomes of 24 vs 48 wk of therapy with pegylated interferon and ribavirin in patients with hepatitis C virus genotype 6. aTreatment duration was tailored according to viral response at week 4: Patients with negative hepatitis C virus-RNA received 24 wk of treatment; the remainder received 48 wk. ns: Non-significant; nr: Not reported.